What is Datavant?
Headquartered in San Francisco, Datavant operates as a specialized software enterprise dedicated to the secure linking and sharing of healthcare data across disparate platforms. By creating a neutral, privacy-preserving environment, the company enables researchers, providers, and payers to derive actionable insights from siloed information. Its core value proposition lies in its ability to bridge the gap between clinical data sources, thereby accelerating the pace of medical research and enhancing the quality of patient care. As a leader in the health tech sector, Datavant provides the essential plumbing for the next generation of data-driven medicine, ensuring that sensitive information remains protected while remaining accessible for authorized analytical purposes.
How much funding has Datavant raised?
Datavant has raised a total of $121M across 3 funding rounds:
Series A
$40.5M
Other Financing Round
$40.5M
Series B
$40M
Series A (2018): $40.5M with participation from Roivant Sciences
Other Financing Round (2018): $40.5M led by Roivant Sciences
Series B (2020): $40M supported by Roivant Sciences Ltd., Johnson & Johnson Innovation – JJDC, Inc., Cigna Ventures, Transformation Capital Group Ltd, and Flex Capital
Key Investors in Datavant
Roivant Sciences
A tech-enabled healthcare organization focused on accelerating the development of late-stage drug candidates and deploying innovative medical technologies.
Johnson & Johnson Innovation – JJDC, Inc.
The strategic venture capital arm of Johnson & Johnson, investing in early-to-mid-stage companies that align with the firm's focus on medical devices, pharmaceuticals, and consumer health.
Cigna Ventures
The corporate venture fund of Cigna, which targets high-growth companies that can improve the health, well-being, and peace of mind of those they serve through digital health and data solutions.
What's next for Datavant?
With the support of its latest capital injection, Datavant is well-positioned to expand its footprint in the enterprise healthcare market. The strategic focus will likely center on deepening its integration capabilities and enhancing its suite of data safety tools to meet the evolving regulatory landscape. As the demand for longitudinal patient data grows, Datavant's role as a trusted intermediary will be instrumental in driving collaborative research initiatives. Future growth will likely involve scaling its platform to accommodate larger datasets and fostering deeper partnerships with global pharmaceutical firms and health systems, further cementing its status as an indispensable utility in the global healthcare economy.
See full Datavant company page
